Aliases & Classifications for Movement Disease

MalaCards integrated aliases for Movement Disease:

Name: Movement Disease 12 14
Movement Disorders 52 41 42 69
Abnormality of Movement 29

Classifications:



External Ids:

Disease Ontology 12 DOID:480
MeSH 42 D009069
NCIt 47 C116757
SNOMED-CT 64 60342002
UMLS 69 C0026650

Summaries for Movement Disease

MedlinePlus : 41 imagine if parts of your body moved when you didn't want them to. if you have a movement disorder, you experience these kinds of impaired movement. dyskinesia is abnormal uncontrolled movement and is a common symptom of many movement disorders. tremors are a type of dyskinesia. nerve diseases cause many movement disorders, such as parkinson's disease. other causes include injuries, autoimmune diseases, infections and certain medicines. many movement disorders are inherited, which means they run in families. treatment varies by disorder. medicine can cure some disorders. others get better when an underlying disease is treated. often, however, there is no cure. in that case, the goal of treatment is to improve symptoms and relieve pain.

MalaCards based summary : Movement Disease, also known as movement disorders, is related to cervical dystonia and stereotypic movement disorder, and has symptoms including ataxia, athetosis and back pain. An important gene associated with Movement Disease is TOR1A (Torsin Family 1 Member A), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Chks in Checkpoint Regulation. The drugs Donepezil and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and heart, and related phenotypes are behavior/neurological and cellular

Related Diseases for Movement Disease

Diseases related to Movement Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 81)
id Related Disease Score Top Affiliating Genes
1 cervical dystonia 32.2 GCH1 TOR1A
2 stereotypic movement disorder 12.3
3 periodic limb movement disorder 12.2
4 extrapyramidal and movement disease 11.8
5 psychogenic movement 11.6
6 mirror movements 1 and/or agenesis of the corpus callosum 11.5
7 ocular motility disease 11.4
8 essential tremor 11.3
9 mental retardation, x-linked 102 11.2
10 dystonia 11.2
11 conversion disorder 11.1
12 13q12.3 microdeletion syndrome 11.0 LRRK2 SNCA
13 blepharospasm 11.0
14 dystonia-11, myoclonic 11.0
15 anismus 10.8 ATP1A3 TOR1A
16 parkinson disease 6, early onset 10.8 PARK7 PINK1
17 microcephaly 18, primary, autosomal dominant 10.8 SLC6A3 SNCA
18 cranio-facial dystonia 10.7 GCH1 TOR1A
19 sebaceous gland disease 10.7 LRRK2 SLC6A3 SNCA
20 vps35-related parkinson disease 10.7 GCH1 TH
21 segmental dystonia 10.7 DRD2 SGCE TOR1A
22 ceroid lipofuscinosis, neuronal, 2 10.6 GCH1 TH
23 riedel's fibrosing thyroiditis 10.6 LRRK2 MAPT SNCA
24 bladder hepatoid adenocarcinoma 10.6 DRD2 SLC6A3 SNCA
25 nosophobia 10.6 LRRK2 MAPT SNCA
26 hereditary paraganglioma-pheochromocytoma syndromes 10.6 GCH1 TH
27 corneal endothelial dystrophy, autosomal recessive 10.6 FTL PANK2 SNCA
28 rubinstein-taybi syndrome 2 10.5 PINK1 PRKN
29 penis basal cell carcinoma 10.5 MAPT SLC6A3
30 perry syndrome 10.5 SLC6A3 SNCA TH
31 pyromania 10.5 DRD2 DRD3 SLC6A3
32 hereditary spastic paraplegia 3a 10.5 FTL PANK2 SNCA
33 leukodystrophy, hypomyelinating, 2 10.5 GCH1 HTT PANK2 TOR1A
34 asperger syndrome 10.5 DRD2 DRD3 SLC6A3
35 obstructive sleep apnea 10.5 ATP1A3 GCH1 SGCE SNCA TOR1A
36 acute female pelvic peritonitis 10.5 DRD2 DRD3 SLC6A3
37 ovarian cystadenocarcinoma 10.5 SLC6A3 SNCA TH
38 amyloidosis, finnish type 10.5 GCH1 SGCE TH TOR1A
39 frias syndrome 10.5 GCH1 TH
40 pick disease 10.4 LRRK2 MAPT PRKN SNCA
41 alternating hemiplegia of childhood 2 10.4 ATP1A3 GCH1 PANK2 SGCE TOR1A
42 cecal benign neoplasm 10.4 DRD2 DRD3 SLC6A3
43 piebald trait, kit-related 10.4 LRRK2 MAPT PARK7 SNCA
44 colon mucinous adenocarcinoma 10.4 DRD2 DRD3 SLC6A3
45 placenta disease 10.4 DRD2 DRD3 TH
46 heroin dependence 10.4 DRD2 DRD3 SLC6A3
47 osteogenesis imperfecta, type ix 10.4 DRD2 SGCE SLC6A3
48 pauci-immune glomerulonephritis with anca 10.4 DRD2 DRD3 TH
49 supranuclear palsy, progressive 10.4
50 stiff-person syndrome 10.4

Graphical network of the top 20 diseases related to Movement Disease:



Diseases related to Movement Disease

Symptoms & Phenotypes for Movement Disease

UMLS symptoms related to Movement Disease:


ataxia, athetosis, back pain, dystonia, headache, leg cramps, muscle cramp, myoclonus, pain, sciatica, seizures, spasm, syncope, torticollis, tremor, chronic pain, cogwheel rigidity, spasmodic torticollis, muscle fibrillation, asterixis, clumsiness, hyperexplexia, akathisia, involuntary movements, abnormal head movements, vertigo/dizziness, abnormal coordination, myokymia, sleeplessness, symptoms, pseudobulbar signs

MGI Mouse Phenotypes related to Movement Disease:

44 (show all 13)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.48 ATP1A3 DRD2 DRD3 FMR1 GAMT HTT
2 cellular MP:0005384 10.4 TH TOR1A DRD2 FMR1 GAMT HTT
3 growth/size/body region MP:0005378 10.36 PRKN SLC2A1 SLC6A3 SNCA TH TOR1A
4 homeostasis/metabolism MP:0005376 10.34 ATP1A3 DRD2 DRD3 GAMT HTT LRRK2
5 mortality/aging MP:0010768 10.24 ATP1A3 DRD2 DRD3 GAMT HTT LRRK2
6 cardiovascular system MP:0005385 10.21 DRD2 DRD3 HTT LRRK2 MAPT PINK1
7 nervous system MP:0003631 10.19 FMR1 HTT LRRK2 MAPT PANK2 PARK7
8 endocrine/exocrine gland MP:0005379 10.18 DRD2 FMR1 GAMT HTT LRRK2 PANK2
9 integument MP:0010771 10.06 FMR1 HTT LRRK2 MAPT PRKN SLC6A3
10 muscle MP:0005369 9.92 ATP1A3 DRD2 MAPT PANK2 PRKN SGCE
11 no phenotypic analysis MP:0003012 9.81 HTT LRRK2 MAPT PINK1 PRKN SLC2A1
12 renal/urinary system MP:0005367 9.5 DRD2 DRD3 GAMT LRRK2 MAPT PANK2
13 taste/olfaction MP:0005394 9.1 DRD2 HTT MAPT PINK1 SLC6A3 SNCA

Drugs & Therapeutics for Movement Disease

Drugs for Movement Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 908)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Donepezil Approved Phase 4,Phase 3,Phase 1,Phase 2 120014-06-4 3152
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
3
Galantamine Approved Phase 4,Phase 3,Phase 2 357-70-0 9651
4
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
5
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-84-3 187
6
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 2078-54-8 4943
7
Sevoflurane Approved, Vet_approved Phase 4,Phase 2,Phase 1 28523-86-6 5206
8
Citalopram Approved Phase 4,Phase 2,Phase 3 59729-33-8 2771
9
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
10
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2180-92-9, 38396-39-3 2474
11
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 51-43-4 5816
12
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2 76-42-6 5284603
13 Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1
14
Levobupivacaine Approved Phase 4 27262-47-1 92253
15
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2 57-27-2 5288826
16
Lactulose Approved Phase 4,Phase 3,Phase 2 4618-18-2 11333
17
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2 80621-81-4 6436173
18
Levodopa Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-92-7 6047
19
Rasagiline Approved Phase 4,Phase 2,Phase 3,Phase 1 136236-51-6 3052776
20
Nicotine Approved Phase 4,Phase 2,Phase 1 54-11-5 942 89594
21
Memantine Approved, Investigational Phase 4,Phase 2 19982-08-2 4054
22
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2 148553-50-8 5486971
23
Pramipexole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 104632-26-0 59868 119570
24
Ropinirole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 91374-20-8, 91374-21-9 5095 497540
25
Rivastigmine Approved, Investigational Phase 4,Phase 3,Phase 2 123441-03-2 77991
26
Clonidine Approved Phase 4,Phase 3,Phase 2 4205-90-7 2803
27
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
28
Amantadine Approved Phase 4,Phase 3,Phase 2,Phase 1 768-94-5 2130
29
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2 76631-46-4, 113775-47-6 68602 5311068 56032
30
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 1 59467-70-8 4192
31
Remifentanil Approved Phase 4,Phase 3,Phase 1,Phase 2 132875-61-7 60815
32
Apomorphine Approved, Investigational Phase 4,Phase 3,Phase 2 41372-20-7, 58-00-4 6005
33
Carbidopa Approved Phase 4,Phase 3,Phase 2,Phase 1 28860-95-9 34359 38101
34
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129722-12-9 60795
35
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
36
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 132539-06-1 4585
37
Entacapone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 130929-57-6 5281081
38
Diclofenac Approved, Vet_approved Phase 4,Phase 3 15307-86-5 3033
39 Piracetam Approved Phase 4,Phase 3,Phase 2 7491-74-9
40
Zinc Approved Phase 4,Phase 3,Phase 2 7440-66-6 32051 23994
41
Amoxicillin Approved, Vet_approved Phase 4,Phase 3 26787-78-0 33613 2171
42
Diphenhydramine Approved Phase 4,Phase 3,Phase 2 58-73-1, 147-24-0 3100
43
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 75614-87-8, 51-45-6 774
44
Promethazine Approved Phase 4,Phase 3,Phase 2 60-87-7 4927
45
Ropivacaine Approved Phase 4,Phase 3,Phase 2 84057-95-4 71273 175805
46
Tetrabenazine Approved Phase 4,Phase 3 58-46-8 6018
47
Zonisamide Approved, Investigational Phase 4,Phase 2,Phase 3 68291-97-4 5734
48
Baclofen Approved Phase 4,Phase 3,Early Phase 1 1134-47-0 2284
49
Acetaminophen Approved Phase 4,Phase 3,Phase 1 103-90-2 1983
50
Selegiline Approved, Investigational, Vet_approved Phase 4,Phase 2 14611-51-9 26757 5195

Interventional clinical trials:

(show top 50) (show all 4667)

id Name Status NCT ID Phase Drugs
1 Validation of DaTscan for Detection of Parkinson Disease Related Disorders Unknown status NCT02138682 Phase 4 l-123 Ioflupane
2 The Effect of Donepezil on Gait and Balance in Parkinson's Disease Unknown status NCT01521117 Phase 4 Donepezil
3 The Relationship Between Risperdal Treatment and Quality of Life in Patients With Alzheimer's Disease and Behavioural and Psychological Symptoms of Dementia (BPSD) Unknown status NCT00626613 Phase 4 Risperdal,reminyl
4 The Use of Botox in Advanced Parkinson's Patients Experiencing Pain Unknown status NCT02472210 Phase 4 Botulinum Toxin
5 Anesthesia Induction in Patients Undergoing Surgery for Cervical Myelopathy Unknown status NCT01052337 Phase 4 anaesthetics: sevofluorane
6 Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder Unknown status NCT00442481 Phase 4 Escitalopram
7 Lactobacillus Reuteri in Children With Constipation Unknown status NCT01388712 Phase 4
8 Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome Unknown status NCT01823770 Phase 4 Rotigotine;Placebo patchs
9 Comparison of the Local Anaesthetics Articaine and Bupivacaine in Treatment of Acute Sternum Pain After Heart Surgery Unknown status NCT01536717 Phase 4 Articaine hydrochloride 2% solution;Sodium Chloride
10 The Analgesic Efficacy of Local Anaesthetic Wound Infiltration Versus Intrathecal Morphine for Total Knee Replacement Unknown status NCT01312415 Phase 4 Levobupivacaine;Intrathecal morphine
11 Rifaximin Versus Lactulose in Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
12 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
13 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
14 Creative Therapy to Affect Stroke Outcomes Unknown status NCT01455155 Phase 4
15 The Analgesic Efficacy of Periarticular Infiltration of Local Anaesthetic for Total Hip Replacement Unknown status NCT01312077 Phase 4 Levobupivacaine;Intrathecal morphine
16 Quadripolar Leads for the Management of Heart Failure Patients in the Middle East Unknown status NCT02195843 Phase 4
17 Controlled Trial of Deep Brain Stimulation in Early Patients With Parkinson's Disease Unknown status NCT00354133 Phase 4
18 Effect of Deep Brain Stimulation on Gait of Patients With Parkinson's Disease Depending on Electrode Location in Subthalamic Area Unknown status NCT01782638 Phase 4
19 Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study Unknown status NCT01765257 Phase 4 AZILECT®;Placebo
20 Nicotine Treatment of Impulsivity in Parkinson's Disease Unknown status NCT01216904 Phase 4 nicotine patch;placebo
21 The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease Unknown status NCT00696215 Phase 4 placebo;rasagiline
22 Study of Memantine to Treat Huntington's Disease Unknown status NCT00652457 Phase 4 Memantine
23 Emotion, Mood and Executive Function in Parkinson`s Disease (PD) Unknown status NCT01385735 Phase 4 Rasagiline;Placebo
24 Botulinum A Toxin in Patients With Parkinson's Disease Unknown status NCT00822913 Phase 4 Intravesical injection of Botulinum A toxin
25 Effects of Functional Electrical Stimulation on Gait in Children With Cerebral Palsy Unknown status NCT02462018 Phase 4
26 Perioperative Pregabalin Use, Rehabilitation, Pain Outcomes and Anxiety Following Hip Surgery Unknown status NCT00762099 Phase 4 Pregabalin;Placebo
27 Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID) Unknown status NCT01515774 Phase 4 Mirapex ER
28 A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients Unknown status NCT01007630 Phase 4 Rasagiline;Placebo
29 Memantine for Post-Operative Pain Control Unknown status NCT01041313 Phase 4 Memantine;Placebo
30 Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients Unknown status NCT01780467 Phase 4
31 Cognitive Decline in Non-demented PD Unknown status NCT01340885 Phase 4 Strattera;Exelon
32 Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD Unknown status NCT00152750 Phase 4 APO-clonidine
33 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
34 Influence of Profound Muscle Relaxation on Muscle Trauma and Postoperative Pulmonary Function Unknown status NCT01804933 Phase 4 profound neuromuscular blockade
35 Effects of Botulinum Toxin Type A(Meditoxin®) on Sleep Bruxism Unknown status NCT01336439 Phase 4 Botulinum toxin type A (Meditoxin®)
36 The Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy Unknown status NCT01313819 Phase 4 PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj
37 Incidence of Acute Cerebrovascular Events Using Either Minimized or Standard Cardiopulmonary Bypass Circuit Unknown status NCT00862160 Phase 4
38 Safety Evaluation of Dexmedetomidine for EBUS-TBNA Unknown status NCT01381627 Phase 4 Remifentanil;Dexmedetomidine
39 FINGER Robot Therapy Study Unknown status NCT02048826 Phase 4
40 Efficacy and Safety of DBS of the GPi in Patients With Primary Generalized and Segmental Dystonia Unknown status NCT00142259 Phase 4
41 Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists Completed NCT00443872 Phase 4 orally disintegrating selegiline (Zelapar)
42 Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia Completed NCT00950196 Phase 4 amantadine sulphate
43 Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) Completed NCT01770145 Phase 4 APOKYN;L-dopa;Trimethobenzamide
44 The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients Completed NCT00480870 Phase 4 donepezil;Placebo
45 Amitiza in Constipation Associated With PD (Parkinson's Disease) Completed NCT00908076 Phase 4 LUBIPROSTONE
46 Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms Completed NCT00297778 Phase 4 Pramipexole
47 Namenda (Memantine) for Non-Motor Symptoms in Parkinson's Disease Completed NCT00646204 Phase 4 Memantine;placebo
48 Bradykinesia Subscale Administered Alone Versus Regular Administration: Psychometric Properties Completed NCT00932581 Phase 4
49 Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease Completed NCT01032486 Phase 4 Rasagiline mesylate
50 Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease Completed NCT00526630 Phase 4 Methylphenidate (MPD);Placebo

Search NIH Clinical Center for Movement Disease

Cochrane evidence based reviews: movement disorders

Genetic Tests for Movement Disease

Genetic tests related to Movement Disease:

id Genetic test Affiliating Genes
1 Abnormality of Movement 29

Anatomical Context for Movement Disease

MalaCards organs/tissues related to Movement Disease:

39
Brain, Eye, Heart, Testes, Breast, Spinal Cord, Subthalamic Nucleus

Publications for Movement Disease

Articles related to Movement Disease:

id Title Authors Year
1
Muscle co-activity tuning in Parkinsonian hand movement: disease-specific changes at behavioral and cerebral level. ( 26300761 )
2015

Variations for Movement Disease

Copy number variations for Movement Disease from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 262562 X 37500000 47300000 Deletion MAOA Movement disorder
2 262566 X 37500000 47300000 Deletion MAOB Movement disorder

Expression for Movement Disease

Search GEO for disease gene expression data for Movement Disease.

Pathways for Movement Disease

GO Terms for Movement Disease

Cellular components related to Movement Disease according to GeneCards Suite gene sharing:

(show all 24)
id Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.91 ATP1A3 LRRK2 MAPT SLC6A3 SNCA TH
2 membrane raft GO:0045121 9.88 LRRK2 PARK7 SLC2A1 SLC6A3
3 cytoplasmic vesicle membrane GO:0030659 9.83 HTT SNCA TH TOR1A
4 perikaryon GO:0043204 9.8 DRD2 FMR1 LRRK2 TH
5 dendrite GO:0030425 9.8 DRD2 FMR1 HTT LRRK2 MAPT SGCE
6 cell body GO:0044297 9.78 MAPT PARK7 PINK1
7 synaptic vesicle GO:0008021 9.78 LRRK2 SNCA TH TOR1A
8 mitochondrial intermembrane space GO:0005758 9.77 PANK2 PARK7 PINK1
9 terminal bouton GO:0043195 9.74 LRRK2 SNCA TH
10 axon terminus GO:0043679 9.73 DRD2 FMR1 SNCA
11 postsynapse GO:0098794 9.71 FMR1 LRRK2 SNCA
12 presynapse GO:0098793 9.71 FMR1 PARK7 PRKN SLC6A3
13 neuron projection GO:0043005 9.7 FMR1 LRRK2 PARK7 PRKN SLC6A3 TH
14 inclusion body GO:0016234 9.63 HTT LRRK2 SNCA
15 sarcolemma GO:0042383 9.62 ATP1A3 SGCE
16 autolysosome GO:0044754 9.58 FTL LRRK2
17 Lewy body GO:0097413 9.51 PINK1 PRKN
18 axon GO:0030424 9.36 ATP1A3 DRD2 FMR1 HTT LRRK2 MAPT
19 growth cone GO:0030426 9.35 FMR1 LRRK2 MAPT SNCA TOR1A
20 cytoplasm GO:0005737 10.25 ATP1A3 FMR1 GAMT GCH1 HTT LRRK2
21 cytosol GO:0005829 10.24 FMR1 FTL GAMT GCH1 HTT LRRK2
22 cell projection GO:0042995 10.09 DRD3 FMR1 LRRK2 MAPT SGCE TOR1A
23 perinuclear region of cytoplasm GO:0048471 10.02 FMR1 HTT PARK7 PINK1 PRKN SNCA
24 synapse GO:0045202 10 ATP1A3 FMR1 LRRK2 SNCA TOR1A

Biological processes related to Movement Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of neuron apoptotic process GO:0043524 9.98 PARK7 PINK1 PRKN SNCA
2 response to oxidative stress GO:0006979 9.98 LRRK2 PINK1 PRKN TOR1A
3 response to ethanol GO:0045471 9.95 DRD2 DRD3 SLC6A3 TH
4 cellular response to oxidative stress GO:0034599 9.92 LRRK2 PARK7 PINK1 SNCA
5 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.91 PARK7 PINK1 SNCA
6 mitochondrion organization GO:0007005 9.91 LRRK2 PARK7 PINK1 PRKN
7 memory GO:0007613 9.9 ATP1A3 MAPT TH
8 learning GO:0007612 9.89 DRD3 PRKN TH
9 regulation of autophagy GO:0010506 9.88 LRRK2 MAPT PRKN
10 negative regulation of protein phosphorylation GO:0001933 9.88 LRRK2 PARK7 PRKN SNCA
11 visual learning GO:0008542 9.87 ATP1A3 DRD2 DRD3
12 protein destabilization GO:0031648 9.87 HTT PRKN SNCA
13 response to nicotine GO:0035094 9.86 DRD2 SLC6A3 TH
14 adult locomotory behavior GO:0008344 9.86 ATP1A3 PARK7 PRKN SNCA
15 negative regulation of neuron death GO:1901215 9.85 LRRK2 PARK7 PRKN SNCA
16 response to cocaine GO:0042220 9.83 DRD2 DRD3 SLC6A3 SNCA
17 locomotory behavior GO:0007626 9.83 DRD2 DRD3 PRKN SLC6A3 TH
18 negative regulation of blood pressure GO:0045776 9.82 DRD2 DRD3 GCH1
19 response to amphetamine GO:0001975 9.82 DRD2 DRD3 TH
20 regulation of reactive oxygen species metabolic process GO:2000377 9.8 PINK1 PRKN SNCA
21 behavioral response to cocaine GO:0048148 9.78 DRD2 DRD3 SNCA
22 regulation of neurotransmitter secretion GO:0046928 9.77 FMR1 PRKN SNCA
23 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.77 LRRK2 PARK7 PRKN
24 regulation of mitochondrial membrane potential GO:0051881 9.76 PANK2 PARK7 PINK1 PRKN
25 regulation of protein ubiquitination GO:0031396 9.75 PINK1 PRKN
26 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.75 LRRK2 PARK7
27 microglial cell activation GO:0001774 9.75 MAPT SNCA
28 positive regulation of mitochondrial fission GO:0090141 9.75 PINK1 PRKN
29 startle response GO:0001964 9.75 DRD2 PRKN
30 cellular response to dopamine GO:1903351 9.75 LRRK2 PRKN
31 neurotransmitter biosynthetic process GO:0042136 9.75 SLC6A3 TH
32 regulation of mitochondrion organization GO:0010821 9.74 PINK1 PRKN
33 negative regulation of voltage-gated calcium channel activity GO:1901386 9.74 DRD2 FMR1
34 negative regulation of macroautophagy GO:0016242 9.74 LRRK2 PINK1
35 supramolecular fiber organization GO:0097435 9.74 MAPT SNCA
36 positive regulation of renal sodium excretion GO:0035815 9.74 DRD2 DRD3
37 negative regulation of oxidative stress-induced neuron death GO:1903204 9.74 PARK7 PINK1
38 negative regulation of autophagosome assembly GO:1902902 9.74 LRRK2 PINK1
39 prepulse inhibition GO:0060134 9.74 DRD2 DRD3 SLC6A3
40 synaptic vesicle transport GO:0048489 9.73 SNCA TOR1A
41 G-protein coupled receptor internalization GO:0002031 9.73 DRD2 DRD3
42 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.73 DRD2 DRD3
43 regulation of phosphoprotein phosphatase activity GO:0043666 9.73 DRD2 HTT
44 regulation of dopamine metabolic process GO:0042053 9.73 PRKN SLC6A3
45 cerebral cortex development GO:0021987 9.72 ATP1A3 TH
46 adenohypophysis development GO:0021984 9.72 DRD2 SLC6A3
47 regulation of mitochondrial fission GO:0090140 9.72 LRRK2 MAPT
48 intracellular distribution of mitochondria GO:0048312 9.71 LRRK2 MAPT
49 cellular response to toxic substance GO:0097237 9.71 PINK1 PRKN
50 regulation of protein targeting to mitochondrion GO:1903214 9.71 PINK1 PRKN

Molecular functions related to Movement Disease according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.99 DRD2 FMR1 GCH1 LRRK2 MAPT PARK7
2 microtubule binding GO:0008017 9.78 FMR1 LRRK2 MAPT SNCA
3 enzyme binding GO:0019899 9.77 MAPT PARK7 PRKN SNCA TH
4 drug binding GO:0008144 9.7 DRD2 DRD3 SLC6A3
5 ubiquitin-specific protease binding GO:1990381 9.57 PARK7 PRKN
6 phospholipase binding GO:0043274 9.56 PRKN SNCA
7 ferric iron binding GO:0008199 9.55 FTL TH
8 tubulin binding GO:0015631 9.5 LRRK2 MAPT PRKN
9 dynactin binding GO:0034452 9.49 HTT MAPT
10 D1 dopamine receptor binding GO:0031748 9.46 ATP1A3 DRD3
11 kinase binding GO:0019900 9.46 HTT PARK7 PRKN SLC2A1
12 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.43 DRD2 DRD3
13 cuprous ion binding GO:1903136 9.4 PARK7 SNCA
14 identical protein binding GO:0042802 9.32 DRD2 FMR1 FTL HTT LRRK2 MAPT
15 dopamine neurotransmitter receptor activity GO:0004952 9.26 DRD2 DRD3
16 dopamine binding GO:0035240 9.26 DRD2 DRD3 SLC6A3 TH
17 protein binding GO:0005515 10.44 DRD2 DRD3 FMR1 FTL GCH1 HTT

Sources for Movement Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....